Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response
➤ First patient receives investigational surgical system for glaucoma
➤ Clinical program for RP gene therapy begins
➤ FDA approves IND for steroid-free, topical anti-inflammatory
➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ Enrollment complete in first-in-human trial evaluating treatment for patients with Usher syndrome
➤ First patients randomized in drug-eluting IOL trial
➤ Preliminary data from Phase 2 gene modifier study for geographic atrophy
➤ ASCRS news and events
➤ Study: ‘revolutionary,’ ‘world-first’ treatment for vision-threatening condition restores sight ➤ IDE granted to tissue-based presbyopia solution ➤ Fast Track designation granted for geographic atrophy treatment ➤ Phase 1 results for Stargardt gene therapy ➤ Topline Phase 1b results from study comparing a next-gen treatment to faricimab ➤ Enrolled patients complete dosing in part of trial evaluating X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
➤ FDA accepts BLA for thyroid eye treatment
➤ Breakthrough Therapy Designation granted to investigational neuroprotective for optic neuropathies
➤ FDA issues complete response letter for wet AMD BLA resubmission
➤ Biosimilar approved for retinal therapies
➤ FDA approves IND for corneal genome editing program
➤ Study: ‘largest prospective trial ever’ on postcataract endophthalmitis prophylaxis
➤ Complimentary access to video journal
➤ Company news
➤ ASCRS news and events
➤ FDA review extended for dry eye disease treatment
➤ Key data gathered for expected NDA submission
➤ Phase 2b results for GA treatment
➤ Phase 3 studies discontinued for thyroid eye disease
➤ ASCRS news and events
➤ FDA grants IDE for synthetic endothelial layer study
➤ NDA submission for wet AMD treatment advances
➤ Positive feedback moves forward NDA submission plans
➤ Company news
➤ ASCRS news and events
The performance of a pars plana anterior vitrectomy can be an essential skill in select circumstances. Two physicians discussed when this approach may best be utilized, benefits of it, and other nuances.
➤ FDA approves treatment for macular edema following RVO
➤ New cyclosporine product receives approval for dry eye
➤ First human implant of 3D-bioprinted cornea
➤ Topline results from Phase 3 trial for Stargardt disease
➤ First patient treated with IDE glaucoma therapy
➤ Enrollment complete for Phase 2 trial for geographic atrophy treatment
➤ First patient implanted with investigational glaucoma shunt in trial
➤ Positive review of Phase 3 pivotal trial for AMD
➤ Company news
➤ ASCRS news and events
➤ 510(k) clearance granted to auto kerato-refracto tonometer
➤ First patient dosed with gene therapy for Best disease
➤ Long-term data shows therapy delays geographic atrophy progression
➤ Lead gene therapy candidate to treat wet AMD and DME announced
➤ FDA accepts BLA resubmission
➤ Company news
➤ ASCRS news and events
➤ Meeting with FDA to advance therapy for Leber congenital amaurosis
➤ 36-month data from first-in-human bimatoprost-IOL system
➤ 20-week data from study evaluating treatment for patients with macular edema secondary to inflammation
➤ Interim data from Phase 1/2 trial for wet AMD therapy
➤ Company news
➤ ASCRS news and events
